Robert Hsu

Assistant Professor of Clinical Medicine

Director of LAC Lung Medical Oncology

Image of Robert Hsu
Is this your profile? Click to edit

Overview

Dr. Robert Hsu is an Assistant Professor of Medicine in the Division of Medical Oncology at University of Southern California focusing on thoracic cancers. Dr. Hsu completed his medical school training at Tulane University School of Medicine followed by Internal Medicine residency training at University of Miami/Jackson Memorial and then hematology and oncology training at Los Angeles County+University of Southern California where he served as chief fellow for medical oncology.

His research interests are focused in lung cancer research along with cancer disparities across multiple solid tumor types. His research includes projects involving comprehensive genomic profiling looking at biomarkers in lung cancer, retrospective database work looking at lung cancer patients treated at USC looking at mutation differences among different ethnicities particularly Hispanics, epidemiological research looking at lung and thyroid cancer incorporating the California Cancer Registry, and translational research looking at tumor microenvironment and ethnicities in lung and breast cancer.

Awards

  • National Institutes of Health: NIH Summer Student Intramural Award, 2007
  • Cornell University: Cornell University Community Partnership Grant, 2008
  • Cornell University: Cum Laude Distinction, 2009
  • AmeriCorps: AmeriCorps Segal Education Award, 2010
     – 2011
  • Tulane University School of Medicine: Southern Section-American Federation for Clinical Research Travel Award, 2014
  • Asian Pacific American Medical Student President’s Award for Distinguished Service, 2017
  • Summit on National and Global Cancer Health Disparities Travel Award, 2018
  • University of Southern California: Best Research Award at USC Medical Oncology Fellows Research Symposium, 2021
     – 2022
  • International Association for the Study of Lung Cancer: Academy Award, 2024

Education and Training

  • Cornell University, Ithaca, NY — BS — 2009 — Biological Sciences & Biometry & Statistics
  • University of Toledo, Toledo, OH — MS — 2012 — Biomedical Sciences
  • Tulane University School of Medicine, New Orleans, LA — MD — 2016
  • University of Miami/Jackson Memorial Hospital, Miami, FL — 2019 — Residency, Internal Medicine
  • University of Southern California, Los Angeles, CA — 2022 — Fellowship, Hematology & Oncology

Research Funding

  • A phase II study of subcutaneous atezolizumab in NSCLC patients using a decentralized clinical trial model
    Robert A. Winn Excellence in Clinical Trials Career Development Award · Oct 1, 2024 – Jan 1, 2027

Research Keywords

  • Cancer Disparities
  • Cancer Tumor Microenvironment/Immunotherapy
  • Lung Cancer
  • Hispanic and Asian Pacific Islander Health

Publications

  • Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review. Cancers (Basel). 2026 Jul 16; 18(14).. View in PubMed
  • Thrombotic Thrombocytopenic Purpura in a Patient With Triple-Negative Breast Cancer Treated With PD-L1 Inhibition and Taxane Chemotherapy. Clin Case Rep. 2026 Mar; 14(3):e72247.. View in PubMed
  • Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2026; 18:17588359261423890.. View in PubMed
  • DIP-like Adenocarcinoma Presenting as a Part-Solid Nodule: A Case Report. Clin Med Insights Case Rep. 2026; 19:11795476261416241.. View in PubMed
  • Dual-edged therapy: corticosteroids in the era of immunotherapy. Immunotherapy. 2025 Dec-Dec; 17(17-18):1215-1217.. View in PubMed
  • Editorial: Streamlining drug approvals: addressing policy challenges in genitourinary oncology. Front Immunol. 2025; 16:1757428.. View in PubMed
  • Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC. Antibodies (Basel). 2026 Jan 04; 15(1).. View in PubMed
  • Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry. JCO Precis Oncol. 2025 Dec; 9:e2500526.. View in PubMed
  • Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry. Clin Cancer Res. 2025 Sep 15; 31(18):3922-3931.. View in PubMed
  • Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients. Cancer Res Commun. 2025 07 01; 5(7):1082-1094.. View in PubMed